Endometrial Cancer | Primary Research (KOL's Insight) | Market Intelligence | Epidemiology & Market Forecast-2035

The most common type of endometrial cancer, also known as corpus uterine cancer or corpus cancer in the developed world, is adenocarcinoma of the endometrium. Adenocarcinoma of the endometrium, which is more common than cervical carcinoma in less developed countries, is the most common type of gynecological cancer in industrialized countries. After a diagnosis of endometrial cancer, surgery is the first step in the standard management of the condition, which is then followed by chemotherapy and/or radiation therapy. In cases of recurrent disease, secondary cytoreduction has been connected to progression-free and overall survival (PFS).

Description

The most common type of endometrial cancer, also known as corpus uterine cancer or corpus cancer in the developed world, is adenocarcinoma of the endometrium. Adenocarcinoma of the endometrium, which is more common than cervical carcinoma in less developed countries, is the most common type of gynaecological cancer in industrialized countries. Endometrial cancer is expected to have caused 63,230 new cases in the United States, accounting for 3.6 % of all new cancer cases; 11,350 of these women are expected to pass away from the disease in 2018 (1.9% of all cancer deaths). In the early 20th century, cervical cancer claimed more lives in the US than any other cancer, but in the decades that followed, uterine cervical malignancy incidence sharply decreased. This decline (Pap smear) has been associated with screening with the Papanicolaou test results. Since cervical cancer screenings are infrequent in these countries, cervical cancer is particularly prevalent there.

Endometrial Cancer (Epidemiology)

For every 100,000 females in the US, there are 25.7 cases of endometrial cancer each year. The chance of getting this illness over the course of one's lifetime is 2.8% for American women. Diagnostic rates are highest between the ages of 55 and 64 (median 62 years). Endometrial cancer is much more lethal in Black women (8.1 versus 4.2 deaths/100,000 per year) than it is in white women, despite the fact that there is a slight difference between their risk of developing the disease (24.8 compared to 26.3 new cases/100,000 per year) and their white counterparts' risk of dying from the disease. The gap may be due to a significant rise in the incidence of aggressive endometrial cancer histotypes, such as high-grade endometrioid and clear cell carcinomas, ESC, carcinosarcomas, and endometrial stromal sarcomas, in Black women.

Endometrial Cancer -Current Market Size & Forecast Trends

The global market for endometrial cancer is projected to experience substantial growth, with estimates indicating a size of approximately USD 27.81 billion in 2023, expected to reach around USD 51.15 billion by 2034, reflecting a compound annual growth rate (CAGR) of 5.7% during this period. This growth is driven by the rising incidence of endometrial cancer, advancements in early detection and diagnosis, and an increasing number of research and development initiatives in oncology. The market is characterized by the adoption of personalized medicine and targeted therapies, which are anticipated to further fuel growth. North America is expected to dominate the market due to its advanced healthcare infrastructure and significant investments in cancer research, while regions like Asia-Pacific are projected to witness rapid growth as healthcare access improves. Overall, the endometrial cancer market is well-positioned for continued expansion through 2035 as new therapies and diagnostic technologies emerge.

After a diagnosis of endometrial cancer, surgery is the first step in the standard management of the condition, which is then followed by chemotherapy and/or radiation therapy. Secondary cytoreduction has been associated with progression-free and overall survival (PFS) in patients with recurrent disease. Following surgical resection, the absence of residual disease and the histotype were prognostic indicators for a better long-term OS. Lymph node metastasis should be of particular concern for patients with high-risk early-stage or advanced endometrial cancer. When endometrial cancer is high-risk, either early or advanced, lymph node metastasis is a serious concern. Bendifallah et al developed a predictive model to identify those at high risk for lymph node metastases using the histopathologic features of histologic grade, tumor diameter, depth of myometrial invasion, and status of lymphovascular space involvement after analyzing data from 523 French surgical patients over a 12-year period. According to a different study by Fotopoulou et al, when lymphadenectomy is carried out for patients with high-risk early or advanced disease, the procedure should include the pelvic and para-aortic areas up to the renal vessels to ensure accuracy in the evaluation of all potential positive nodes.

Report Highlights

Endometrial Cancer - Current Market Trends

Endometrial Cancer - Current & Forecasted Cases across the G8 Countries

Endometrial Cancer - Market Opportunities and Sales Potential for Agents

Endometrial Cancer - Patient-based Market Forecast to 2035

Endometrial Cancer - Untapped Business Opportunities

Endometrial Cancer - Product Positioning Vis-a-vis Competitors' Products

Endometrial Cancer - KOLs Insight